Balyasny Asset Management’s Innate Pharma IPHA Stock Holding History

Balyasny Asset Management’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-16,094	Closed	-$32K	–	2993
2022 Q3	$32K	Buy	+16,094	New	+$43.4K	﹤0.01%	2526
2021 Q4	–	Sell	-187,484	Closed	-$1.16M	–	2418
2021 Q3	$1.16M	Buy	+187,484	New	+$808K	﹤0.01%	1296

Other funds holding IPHA

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Balyasny Asset Management's IPHA Position: Q4 2022 in Review

Balyasny Asset Management sold out of Innate Pharma (IPHA) in Q4 2022, closing a stake of 16,094 shares — an estimated $32K sold.

Balyasny Asset Management first reported a position in IPHA in Q3 2021 and held it in 2 quarters. The position peaked at $1.16M in Q3 2021. 11 funds tracked by Wall St. Rank hold IPHA as of Q4 2022.

Balyasny Asset Management reported no remaining Innate Pharma position as of Q4 2022 after selling out during the quarter.
Balyasny Asset Management sold 16,094 Innate Pharma shares in Q4 2022, an estimated $32K.
Balyasny Asset Management first reported a position in Innate Pharma in Q3 2021 and held it in 2 quarters.
Balyasny Asset Management's Innate Pharma position peaked at $1.16M in Q3 2021.
11 funds tracked by Wall St. Rank held Innate Pharma as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.